<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04028401</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0042</org_study_id>
    <nct_id>NCT04028401</nct_id>
  </id_info>
  <brief_title>Optimization of Skin Preparation to Reduce Cutibacterium Acnes Colonization in Superficial and Deep Samples During Prosthetic Shoulder Surgery in Male Patients</brief_title>
  <acronym>OPRICA</acronym>
  <official_title>Optimization of Skin Preparation to Reduce Cutibacterium Acnes Colonization in Superficial and Deep Samples During Prosthetic Shoulder Surgery in Male Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections on joint replacements remain one of the most serious complications of orthopaedic
      surgery. Despite improvements in skin preparation and antibiotic prophylaxis procedures, the
      risk of infection of joint prosthesis is still high, particularly for shoulder prostheses,
      especially in men. One of the bacteria most often involved in post-operative infections for
      shoulder prosthesis is Cutibacterium acnes (CA). This bacterium is one of the predominant
      bacteria in pilosebaceous units. Eradication of this micro-organism remains difficult despite
      the techniques used in the preoperative phase.

      The objective of this protocol is to evaluate the efficacy of applying a 5% benzoyl peroxide
      topical during the 5 days preceding the procedure in the surgical skin incision area, which
      is based on local acne treatment, on the reduction of the CA bacterial load in the dermis of
      the approach to shoulder arthroplasty in men.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients in each group with a positive Cutibacterium acnes sample at the dermis.</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average number of positive intraoperative Cutibacterium acnes samples</measure>
    <time_frame>Day 0</time_frame>
    <description>samples taken at he cutaneous level before and after cutaneous antisepsis of the operating area before incision, fat and capsular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average number of positive Cutibacterium acnes skin samples before and after alcoholic surgical site antisepsis (5% alcoholic iodine povidone) in each of the two study groups</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cutibacterium acnes shoulder prosthesis infections up to 2 years after shoulder prosthesis implantation in both study groups</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phylotype</measure>
    <time_frame>Day 0</time_frame>
    <description>Determination of phylotype by molecular typing by Multi-Locus Sequence Typing and Single-Locus Sequence Typing techniques and comparison of Cutibacterium acnes strains by molecular biology and characterization of antibiotic resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cutibacterium acnes strains</measure>
    <time_frame>Day 0</time_frame>
    <description>Comparison of Cutibacterium acnes strains by molecular biology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic resistance</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the skin tolerance of the topical application from the skin tolerance scale (irritation, erythema and desquamation), at the time of inclusion and at D0</measure>
    <time_frame>Day 0</time_frame>
    <description>skin tolerance scale evaluates local tolerance (absent: 0, light:1, moderate: 2 severe:3), erythema (absent:0, light:1, moderate:2, severe:3, very severe:4) and desquamation (absent: 0, light: 1, moderate: 2, severe: 3, very severe: 4)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cutibacterium Acnes Infection</condition>
  <arm_group>
    <arm_group_label>5 % benzoyl peroxide topical treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of 5% benzoyl peroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No topical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% benzoyl peroxide</intervention_name>
    <description>Application of 5% benzoyl peroxide during 5 days before the procedure</description>
    <arm_group_label>5 % benzoyl peroxide topical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients, Adult patients,

          -  Patient without a history of surgical intervention on the operated shoulder,

          -  Patient managed for glenohumeral, partial (cup or anatomical hemi- arthroplasty) or
             total (anatomical or inverted) glenohumeral arthroplasty placement for primary
             osteoarthritis, or secondary to necrosis, massive rotator cuff tear or old fracture.

          -  Patients affiliated to a social security system

          -  Patients who have given their informed and written consent

        Exclusion Criteria:

          -  Patient with arthroplasty for resumption of previous shoulder surgery or failure of
             arthroplasty

          -  Patient with arthroplasty for acute trauma

          -  Patient on immunosuppressantsimmunosuppressive drugs

          -  Patient with inflammatory rheumatism

          -  Patient with progressive cancer pathology

          -  Allergies or intolerances concerning the modalities of selected skin preparations
             (Povidone Iodine, cefazolin, hypersensitivity to benzoyl peroxide)

          -  Dermatological pathologies in the area to be treated

          -  Acne treatment in the area to be treated within four weeks before inclusion

          -  Patient without possible help from a third party for the application of Cutacnyl® 5%
             in the intervention group if necessary

          -  Major under guardianship

          -  Patient under the protection of justice

          -  Patient not covered by social security
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane CORVEC</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphane CORVEC</last_name>
    <phone>0240083955</phone>
    <phone_ext>+33</phone_ext>
    <email>stephane.corvec@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent HUBERT</last_name>
      <email>LaHubert@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent HUBERT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique LE NEN</last_name>
      <email>dominique.lenen@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique LE NEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane CORVEC</last_name>
    </contact>
    <investigator>
      <last_name>Marc CAPELLI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Michel Sainte Anne</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre SONNARD</last_name>
      <email>a.sonnard@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre SONNARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé THOMAZEAU</last_name>
      <email>herve.thomazeau@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé THOMAZEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Alliance</name>
      <address>
        <city>Saint-Cyr-sur-Loire</city>
        <zip>37540</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe LE DU</last_name>
      <email>dr.christophe.le.du@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Christophe LE DU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Locomoteur de l'Ouest</name>
      <address>
        <city>Saint-Grégoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent BAVEREL</last_name>
      <email>l.baverel@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laurent BAVEREL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santé Atlantique</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44819</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu BOISSARD</last_name>
      <email>drboissard@polyclinique-atlantique.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu BOISSARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc FAVARD</last_name>
      <email>luc.favard@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Luc FAVARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

